Education / Graduate Medical Education / Prospective Fellows / Infectious Diseases Fellowship / Research / Peer Reviewed Publications

Recent Peer Reviewed Publications

1. Samoriski C
2. Chu CY
3. Falsey AR
4. Peterson D
5. Bhattacharya S
6. Croft DP
7. Branche AR
8. Peasley M
9. Baran A
10. Corbett A
11. Ashton J
12. Mariani TJ
13. Walsh EE
Clinical Features and Gene Expression Patterns in Adults Hospitalized With Respiratory Syncytial Virus and Human Metapneumovirus Infection.; The Journal of infectious diseases; Vol 232(Supplement_1), pp. S37-S46. 2025 Jul 16.
1. Branche AR
2. Edwards KM
Review: Knowledge Gained and Gaps in Understanding in the 25 Years Since Human Metapneumovirus Was First Identified as a Cause of Human Disease.; The Journal of infectious diseases; Vol 232(Supplement_1), pp. S1-S9. 2025 Jul 16.
1. Walsh EE
2. Peasley M
3. Branche AR
4. Falsey AR
Respiratory Syncytial Virus Humoral Antibody Responses in Older Adults After Vaccination or Infection.; The Journal of infectious diseases; Vol 231(6), pp. e1146-e1150. 2025 Jul 11.
1. Branche AR
2. Falsey AR
3. Saiman L
4. Alba L
5. Peterson D
6. Wang L
7. Finelli L
8. Walsh EE
Respiratory Syncytial Virus Risk Assessment in Adults: Implications for Vaccine Recommendations Beyond Age.; Open forum infectious diseases; Vol 12(7), pp. ofaf394. 2025 Jul 02.
1. Sudnik P
2. Walsh EE
3. Branche AR
4. Islam M
5. Falsey AR
Comprehensive Analysis of Cardiovascular Events and Risk Factors in Patients Hospitalized with RSV.; Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2025 Jun 12.
1. Jenkins EN
2. Gold JAW
3. Benedict K
4. Lockhart SR
5. Berkow EL
6. Dixon T
7. Shack SL
8. Witt LS
9. Harrison LH
10. Seopaul S
11. Correa MA
12. Fitzsimons M
13. Jabarkhyl Y
14. Barter D
15. Czaja CA
16. Johnston H
17. Markus T
18. Schaffner W
19. Gross A
20. Lynfield R
21. Tourdot L
22. Nadle J
23. Roland J
24. Escutia G
25. Zhang AY
26. Gellert A
27. Hurley C
28. Tesini BL
29. Phipps EC
30. Davis SS
31. Lyman M
Population-Based Active Surveillance for Culture-Confirmed Candidemia - 10 Sites, United States, 2017-2021.; Morbidity and mortality weekly report. Surveillance summaries (Washington, D.C. : 2002); Vol 74(4), pp. 1-15. 2025 May 29.
1. Croft DP
2. Johnston CJ
3. Branche AR
4. Rich DQ
5. Hopke PK
6. Thevenet-Morrison K
7. Thurston SW
8. Jusko TA
9. Islam MR
10. Bunce C
11. Keefer MC
12. Walsh EE
13. Falsey AR
Ambient air pollution exposure and effects on neutralizing antibody titers following SARS-CoV-2 vaccination in adults.; PLOS global public health; Vol 5(5), pp. e0004609. 2025 May 12.
1. Patton ME
2. Moline HL
3. Whitaker M
4. Tannis A
5. Pham H
6. Toepfer AP
7. Taylor CA
8. Goldstein L
9. Reingold A
10. Kirley PD
11. Alden NB
12. Kawasaki B
13. Meek J
14. Kim D
15. Witt LS
16. Openo KP
17. Ryan PA
18. Mumm E
19. Lynfield R
20. Salazar-Sanchez Y
21. Pacheco F
22. Keating F
23. Anderson BJ
24. Tesini BL
25. Felsen CB
26. Sutton M
27. Thomas A
28. Schaffner W
29. Talbot HK
30. Harbi K
31. Doran E
32. Weinberg GA
33. Staat MA
34. Payne DC
35. Halasa NB
36. Stewart L
37. Boom JA
38. Sahni LC
39. Klein EJ
40. Englund JA
41. Williams JV
42. Michaels MG
43. Schuster JE
44. Selvarangan R
45. Szilagyi PG
46. Havers FP
47. Dawood FS
Interim Evaluation of Respiratory Syncytial Virus Hospitalization Rates Among Infants and Young Children After Introduction of Respiratory Syncytial Virus Prevention Products - United States, October 2024-February 2025.; MMWR. Morbidity and mortality weekly report; Vol 74(16), pp. 273-281. 2025 May 08.
1. Andrews LIB
2. Halloran ME
3. Neuzil KM
4. van der Laan L
5. Huang Y
6. Andriesen J
7. Patel M
8. Fisher LH
9. Janes H
10. Rouphael N
11. Walsh SR
12. Theodore DA
13. Tieu HV
14. Sobieszczyk M
15. El Sahly HM
16. Baden LR
17. Falsey AR
18. Campbell TB
19. Kelley CF
20. Healy CM
21. Immergluck L
22. Luft B
23. Hirsch I
24. de Bruyn G
25. Truyers C
26. Priddy F
27. Sumner KM
28. Flannery B
29. Follmann D
30. Gilbert PB
Evaluating the Test-Negative Design for COVID-19 Vaccine Effectiveness Using Randomized Trial Data: A Secondary Cross-Protocol Analysis of 5 Randomized Clinical Trials.; JAMA network open; Vol 8(5), pp. e2512763. 2025 May 01.
1. Atmar RL
2. Lyke KE
3. Posavad CM
4. Deming ME
5. Brady RC
6. Dobrzynski D
7. Edupuganti S
8. Mulligan MJ
9. Rupp RE
10. Rostad CA
11. Jackson LA
12. Martin JM
13. Shriver MC
14. Rajakumar K
15. Coler RN
16. El Sahly HM
17. Kottkamp AC
18. Branche AR
19. Frenck RW
20. Johnston C
21. Babu TM
22. Bäcker M
23. Archer JI
24. Crandon S
25. Nakamura A
26. Nayak SU
27. Szydlo D
28. Dominguez Islas CP
29. Brown ER
30. O'Connell SE
31. Montefiori DC
32. Eaton A
33. Neuzil KM
34. Stephens DS
35. Beigel JH
36. Pasetti M
37. Roberts PC
Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine.; The Journal of infectious diseases. 2025 Apr 29.
1. Riddler SA
2. Moodie Z
3. Clark J
4. Yen C
5. Allen M
6. Furch BD
7. Lu H
8. Grant S
9. Mondal K
10. Anderson M
11. Maenza J
12. Lemos MP
13. Woodward Davis AS
14. Walsh SR
15. Sobieszczyk ME
16. Frank I
17. Goepfert P
18. Stephenson KE
19. Baden LR
20. Tieu HV
21. Keefer MC
22. McElrath MJ
23. Kublin JG
24. Corey L
High Frequency of Chronic Urticaria Following an Investigational HIV-1 BG505 MD39.3 Trimer mRNA Vaccine in a Phase 1, Randomized, Open-Label Clinical Trial (HVTN 302).; Annals of internal medicine. 2025 Apr 29.
1. Moodie Z
2. Li SS
3. Giorgi EE
4. Williams LD
5. Dintwe O
6. Carpp LN
7. Chen S
8. Seaton KE
9. Sawant SS
10. Zhang L
11. Heptinstall J
12. Liu S
13. Grunenberg N
14. Tomaka F
15. Rerks-Ngarm S
16. Pitisuttithum P
17. Nitayaphan S
18. Ake JA
19. Vasan S
20. Pantaleo G
21. Frank I
22. Baden LR
23. Goepfert PA
24. Keefer M
25. Chirenje M
26. Hosseinipour MC
27. Mngadi K
28. Laher F
29. Garrett N
30. Bekker LG
31. De Rosa S
32. Andersen-Nissen E
33. Kublin JG
34. Lu S
35. Gilbert PB
36. Gray GE
37. Corey L
38. McElrath MJ
39. Tomaras GD
A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials.; Emerging microbes & infections; Vol 14(1), pp. 2485317. 2025 Apr 07.
1. Doernberg SB
2. Heil EL
3. Fiawoo S
4. Lee JH
5. Cosgrove SE
6. Dobrzynski DM
7. Li Y
8. Shields RK
9. Spivak ES
10. Stohs EJ
11. Tamma PD
12. McCreary EK
Epidemiology, Treatment, and Outcomes of Gram-Negative Bacteremia in a Multicenter Cohort of Solid Organ Transplant Recipients.; Clinical transplantation; Vol 39(4), pp. e70160. 2025 Apr.
1. Lin LY
2. Ferte T
3. Chachage M
4. Casteano C
5. Laumond G
6. Schmidt S
7. Tahar O
8. Carapito R
9. Bekker LG
10. Churchyard G
11. Keefer M
12. Moodie Z
13. Viegas E
14. Geldmacher C
15. Lhomme E
16. Moog C
Deciphering HIV vaccine-induced Antibody response according to ethnicity.; AIDS (London, England). 2025 Mar 31.
1. Orton KL
2. Monaco CL
The Vaginal Virome in Women's Health and Disease.; Microorganisms; Vol 13(2). 2025 Feb 16.